ValueQ4, 24Q1, 25Q2, 25TTMSelling/general/admin expenses2.83 M2.53 M2.77 M10.63 MResearch & development3.99 M3.93 M3.83 M14.79 M영업 이익-6.62 M-6.35 M-6.51 M-24.88 MNon-Operating Income, Total-1.15 M210 K-374 K-2.25 MInterest expense, net of interest capitalized233 K229 K231 K905 KNon-Operating Income, excl. Interest Expenses-466 K-458 K-462 K-1.81 MUnusual income/expense-920 K439 K-143 K-1.35 MPretax income-8.01 M-6.14 M-6.88 M-27.57 MEquity in earnings————Taxes—-8 000-8 000—Non-controlling/minority interest-171 K-282 K-329 K-970 KAfter tax other income/expense————Net income before discontinued operations-7.6 M-5.85 M-6.54 M-26.14 MDiscontinued operations————Net income-7.6 M-5.85 M-6.54 M-26.14 MDilution adjustment————Preferred dividends————Diluted net income available to common stockholders-7.6 M7.99 B9 B16.98 BBasic earnings per share (Basic EPS)-1.01-0.65-0.71-3.31Diluted earnings per share (Diluted EPS)-1.01-0.65-0.71-3.31Average basic shares outstanding6.34 M9 M9.26 M31.16 MDiluted shares outstanding6.34 M9 M9.26 M31.16 MEBITDA-2.55 M-2.37 M-2.63 M-9.84 MEBIT-2.63 M-2.55 M-2.81 M-10.34 MCost of revenue191 K201 K112 K795 KOther cost of goods sold—436 K497 K—Depreciation & amortization (cash flow)81 K175 K174 K502 K
Pluri Inc
Pluri Inc., formerly Pluristem Therapeutics, is an Israeli company engaged in the development of human placental adherent stromal cells for commercial use in disease treatment. According to the company's website, it extracts adult stem cells exclusively from postnatal placentas.